OBJECTIVE: Postpartum hemorrhage (PPH) remains a leading cause of severe maternal morbidity and mortality. Both regional and national safety initiatives have sought to reduce harm from this condition, yet how to best identify clinically significant PPH episodes is unclear. The objective of this study was to characterize PPH in a major hospital system. STUDY DESIGN: Patients delivering between July 2014 and July 2017 in a four-hospital medical system performing 14,000 deliveries per year were analyzed. Data was obtained by querying the electronic medical record (EMR). Measures of postpartum hemorrhage were classified as: level 1 (any uterotonic), level 2 (ICD 9 or 10 PPH diagnosis code), level 3 (Bakri balloon and/or transfusion 1-3 units RBCs), or level 4 (hysterectomy and/or 4 units RBCs). Hematocrit drop from the last pre-delivery measurement to lowest postpartum level was analyzed in relation to these PPH classifications. For this analysis we presumed hematocrit drop 40% represented major PPH. RESULTS: 43,657 deliveries were included in the analysis including 1621 with level 1, 1326 with level 2, 778 with level 3, and 248 with level 4 PPH. As demonstrated in Figure 1 , PPH categories 3 and 4 were associated with higher proportions of major PPH with 40% hematocrit drops. 30% and 31% of women with PPH level 3 and 4 had hematocrit drops of 40%. 116 women without a diagnosis of PPH (0.4%) had a decrease of this magnitude. The median hematocrit drops for PPH level 1 through 4 were 15.5%, 20.6%, 33.4%, and 33.4%, respectively, versus a 12.6% drop for patients hospitalized for delivery with no PPH (p<0.01). When transfusion was analyzed in relation to hematocrit drop, hematocrit drops were larger for women undergoing transfusion but similar for women receiving 1-3 versus 4 units RBCs (Figure 2) . CONCLUSION: While ICD diagnosis codes and transfusion are commonly used to identify PPH, these measures alone provide a limited view. Additionally, measures of PPH severity such as hematocrit drop may be confounded by transfusion as evidenced by similar hematocrit drop distribution for smaller versus larger transfusion. A robust overview of PPH risk requires assessment of diagnoses, lab changes, uterotonic administration, hysterectomy, and uterine tamponade. For hospitals seeking to analyze quality and safety outcomes related to PPH much of this data may be queried from the EMR. 
